Value
Creation
Model
We catalyze treatments that transform hope into healing
Inputs
Output
Outcomes
FinancialINPUTS
Our financial capital is invested strategically across different therapeutic areas for maximum capital efficiency- Operating Expenses: INR 189 Bn
- CAPEX Allocation: INR 9,402 Mn
OUTPUT
- Revenue from Operations: INR 227 Bn
- EBITDA: INR 54.7 Bn
- Dividend Paid: INR 3,648 Mn
OUTCOMES
A growth driven, competitive, and resilient balance sheet
HumanINPUTS
Our people are our most important assets, and their commitment to patients brings out the best in them- Global Lupin Family: 24,000+
- Expenditure on Benefits: INR 40 Bn
- Total Training Hours: 1,253,456
OUTPUT
- Gender Diversity: 10.4%
- Employee Turnover Rate: 17.19%
- Employee Volunteering Hours: 24,300+
OUTCOMES
A growth centric and diverse workforce
ManufacturingINPUTS
Our 15 state-of-the-art manufacturing facilities pave the way for our sustainable operations to address patient needsOUTPUT
- Manufacturing Output (Formulations): 20,758 Mn Units
- Total Product Portfolio: 1200+ Products
- All Sites are cGMP Compliant
OUTCOMES
Digitally enabled, efficient manufacturing operations
NaturalINPUTS
Our balanced use of natural resources maximizes efficiencies while reducing the impact on environment- Energy Consumption: 2.9 Mn GJ
- Water Withdrawal: 1.77 Mn KL
- Renewable Energy: 39% of total energy
OUTPUT
- Emission Reduction: 26%
- Water Recycling: 44%
- 100% EPR Compliance for Plastic Waste
OUTCOMES
A climate resilient and resource efficient approach to our business
IntellectualINPUTS
Our R&D Centers enable us with a competitive advantage, while making therapies more accessible- R&D Investment: INR 17.7 Bn
- R&D Team: 1400+
- Global R&D Centers: 7
OUTPUT
- Patents Applications in FY25: 50
- Patents Granted in FY25: 87
- Filings in FY25: 41
- Approvals in FY25: 52
OUTCOMES
A focused R&D driving innovation and development of effective and targeted medicines
Social & RelationshipINPUTS
Our communities are extremely important stakeholders, and their enrichment is a priority for us- CSR Spend: INR 247 Mn
- Patient Outreach Programs: 10+
OUTPUT
- Total CSR Beneficiaries: 414,144
- Total Patients Reached: 1.5 Mn+
OUTCOMES
A responsible supply chain and an empowered community
Business Model
Entrepreneurial
Spirit
Customer
Focus
Integrity
Respect and
Care
Passion for
Excellence
Teamwork
Active Pharmaceutical Ingredient
Generics
Complex
Generics
Biotech
OTC
Adjacencies
Assurance Statement